source
- Taiho and Cullinan report positive Phase 3 results for zipalertinib in EGFR exon 20 insertion lung cancerTaiho Oncology and Cullinan Therapeutics announced that their experimental drug zipalertinib achieved positive results in a Phase 3 trial for first‑line treatment of lung cancer patients whose tumo…
- PTC takes a chance on Sangamo’s Fabry disease gene therapyWall Street analysts view the deal as a risky, high-reward bet on a treatment that’s nearing a possible regulatory approval and could be superior to existing medications.BioPharma Dive · 1h ago↗ source